Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01470794 |
Recruitment Status
: Unknown
Verified February 2016 by Tocagen Inc..
Recruitment status was: Active, not recruiting
First Posted
: November 11, 2011
Last Update Posted
: February 25, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glioblastoma Multiforme Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma | Biological: Toca 511 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 58 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A P1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC |
Study Start Date : | January 2012 |
Estimated Primary Completion Date : | May 2016 |
Estimated Study Completion Date : | July 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Toca 511 vector
Toca 511 a retroviral replicating vector expressing the cytosine deaminase enzyme
|
Biological: Toca 511
All subjects will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antibiotic 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, subjects will take a course of oral 5-FC. These courses of 5-FC will be repeated cyclically during the 6-month study.
Other Names:
|
- Dose Limiting Toxicities [ Time Frame: 2 months ]Excluding nausea, vomiting and fatigue, any Grade 3 or higher non-hematologic toxicity or any Grade 4 or higher hematologic toxicity, felt to be related to Toca 511 or the Toca 511/5-FC combination.
- Overall Survival of Subjects [ Time Frame: Overall survival, Overall survival at 6 months (OS6), 9 months (OS9), and 12 months (OS12) ]
- Progression Free Survival (PFS) of Subjects [ Time Frame: PFS of subjects at 6 months (PFS-6) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria (must all be answered "Yes"):
- Has the subject given written informed consent?
- Is the subject between 18 years old and 80 years old inclusive?
- Has the subject had histologically proven HGG with recurrence or progression following initial definitive therapy(s) such as surgery with or without adjuvant radiation therapy and/or chemotherapy (confirmed by diagnostic biopsy or contrast-enhanced MRI and evaluable by Macdonald criteria)? Note if first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
- Does the subject have a single, HGG tumor recurrence/progression that is ≤ 5 cm in its greatest dimension?
- Based on the pre-operative evaluation, is the tumor recurrence/progression a candidate for ≥ 80% resection?
- Has the subject elected not to undergo treatment with the Gliadel® wafer?
- Does the subject have a Karnofsky performance status ≥ 70?
- Does the subject have an absolute neutrophil count (ANC) ≥ 1500/mm3?
- Does the subject have an absolute lymphocyte count ≥ 500/mm3?
- Does the subject have a platelet count ≥ 100,000/mm3?
- Does the subject have a Hgb ≥ 10 g/dL?
- Does the subject have a normal PT/PTT? (subnormal PT/PTT acceptable)
- Does the subject have an estimated glomerular filtration rate of at least 50 mL/min (inclusive) by the Cockcroft-Gault formula?
- Does the subject have an ALT < 3 times the upper limit of the laboratory reference range and total bilirubin < 1.5 mg/dL?
- If the subject is a female of childbearing potential, has she had a negative serum pregnancy test within the past 21 days?
- Is the subject willing to use condoms for contraception for 6 months after receiving Toca 511 or until there is no evidence of the virus in his/her blood, whichever is longer. If the subject is a fertile female, is she willing to use contraception for at least 12 months?
- Is the subject willing and able to abide by the protocol?
Exclusion Criteria (must all be answered "No"):
- Has the subject received cytotoxic chemotherapy within the past 3 weeks (6 weeks for nitrosoureas) of the planned surgery date?
- Does the subject have, or has the subject had, within the past 4 weeks any infection requiring antibiotic, antifungal or antiviral therapy?
- Has the subject had a surgical procedure in the last 28 days or a surgical wound that is not healed?
- Does the subject have any bleeding diathesis, or must the subject take any anticoagulants, or antiplatelet agents, including NSAIDs that cannot be stopped for surgery?
- Does the subject have a history of allergy or intolerance to flucytosine?
- Is the subject HIV positive?
- Does the subject have any gastrointestinal disease that would prevent him or her from being able to ingest or absorb flucytosine?
- Has the subject received any investigational treatment within the past 30 days?
- Is the subject breast feeding?
- Has the subject received Avastin® (bevacizumab) for this recurrence/progression, or within the past 5 weeks?
- Does the patient have a history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than five years?

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01470794
United States, California | |
UCLA | |
Los Angeles, California, United States, 90095 | |
University of California at San Diego | |
San Diego, California, United States, 92093 | |
United States, Michigan | |
Henry Ford Hospital | |
Detroit, Michigan, United States, 48202 | |
United States, New Jersey | |
JFK Medical Center | |
Edison, New Jersey, United States, 08820 | |
United States, Ohio | |
Cleveland Clinic Foundation | |
Cleveland, Ohio, United States, 44195 | |
Ohio State University | |
Columbus, Ohio, United States, 43210 | |
United States, Washington | |
Swedish Neuroscience Institute | |
Seattle, Washington, United States, 98122 |
Responsible Party: | Tocagen Inc. |
ClinicalTrials.gov Identifier: | NCT01470794 History of Changes |
Other Study ID Numbers: |
Tg 511-11-01 |
First Posted: | November 11, 2011 Key Record Dates |
Last Update Posted: | February 25, 2016 |
Last Verified: | February 2016 |
Keywords provided by Tocagen Inc.:
GBM HGG High grade glioma |
Malignant glioma Grade III glioma Grad IV glioma |
Additional relevant MeSH terms:
Glioblastoma Astrocytoma Oligodendroglioma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |